News round-up by DDW’s Reece Armstrong for 13-17 June.
Partnerships, awards, and new companies are some of the topics of this week’s news round-up.
Swiss pharmaceutical company Bachem has partnered with Eli Lilly on a seven-year agreement to advance the development of oligonucleotide-based drug substances.
Contract manufacturing organisation (CMO) KBI Biopharma and cell line development company Selexis have opened an integrated facility in Geneva, Switzerland.
Clinical research organisation (CRO) Celerion has been recognised for its contributions to the industry by claiming an award for the seventh consecutive year.
A University of Cambridge spin-out has secured £2.4 million of investment to help it develop a pipeline of antibody drug conjugate (ADC) therapies for solid tumours.
Diagnostics company Mologic and its sister company Global Access Diagnostics (GAD) have combined their expertise to form a new business aimed at addressing the gaps in the provision of diagnostics, with a focus on expanding affordable access to quality tests.